21st Sep 2015 06:52
LONDON (Alliance News) - Clinigen Group PLC said its Idis Managed Access division has inked a deal with private biopharmaceutical company Neuraltus Pharmaceuticals Inc for a managed access programme for Neuraltus' amyotrophic lateral sclerosis treatment NP001.
Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a fatal neurodegenerative disease. Idis will provide access to the drug for patients who meet eligibility criteria following a request from a physician.
"By partnering with companies like Neuraltus, Idis Managed Access plays a vital role in providing ethical access to unapproved medicines, like NP001, for patients with unmet medical needs," said Managing Director of Idis Simon Estcourt in a statement. "
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L